Drug Search Results
More Filters [+]

Elifactant

Alternative Names: elifactant, chf-5633, chf5633, chf 5633
Latest Update: 2024-04-29
Latest Update Note: PubMed Publication

Product Description

For Treatment of respiratory distress syndrome (RDS) in pre-term babies (Sourced from: https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/elifactant.pdf)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chiesi
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Elifactant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn

Phase 1: Respiratory Insufficiency|Heart Failure, Chronic|Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CCD-05633AA1-02

P2

Completed

Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome

2018-05-24

CCD-1011-PR-0059

P1

Completed

Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn

2015-01-23

22%

2011-001331-22

P1

Completed

Heart Failure, Chronic|Respiratory Insufficiency

2015-01-23

Recent News Events